ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0145

Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care

Yomei Shaw1, Neda Kortam2, Adam Chalak2, Yujia Li2, Faith Reger2, Vivek Nagaraja2 and Dinesh Khanna2, 1University of Michigan, East Lansing, MI, 2University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2021

Keywords: Health Services Research, Patient reported outcomes, Qualitative Research

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Patient-reported outcomes (PROs) are surveys completed by patients to provide measurements of health, quality of life, symptoms, and functional status. PROs are useful for documenting changes in patient’s health status over time as well as facilitating patient-provider communication about symptoms. Despite the potential benefits for the management of rheumatic diseases, uptake of PROs among rheumatology health care providers has been limited. The authors have been developing methods to promote the integration of specific PROs (PROMIS® measures for pain intensity, physical function, and sleep disturbance) into rheumatology care at our institution. To inform our future efforts, we conducted a qualitative study to describe rheumatology provider attitudes towards the feasibility and acceptability of reviewing and discussing PROMIS or other PROs in rheumatology practice.

Methods: In-depth semi-structured interviews were conducted with health care providers at our institution, who were asked to discuss their experiences and attitudes towards the use of PROs in rheumatology care. We recruited providers who had received training on the use of PROMIS as part of a previous study led by 2 of the authors, as well as providers who had not participated in the previous study. The interviews were conducted via phone or video call and lasted between 30-120 minutes. Written informed consent was obtained from participants before the interviews. The interviews were audio recorded and transcribed for analysis.

Qualitative analysis of the transcripts was conducted using NVivo software. Five of the authors carried out the analysis. We used a combination of inductive and deductive coding. Each transcript was coded independently by at least 2 team members, who met to discuss and reconcile any discrepancies in coding that were >=20% for individual codes. The resulting coded data was reviewed and summarized as themes to describe current uptake, perceived benefits and disadvantages, and perceived barriers and facilitators of using PROMIS/PROs.

Results: The 8 health care providers interviewed included 7 physicians and 1 advanced nurse practitioner; 6 of these currently used PROMIS or other PROs in clinical care (Table 1). Two of the providers were trained in the use of PROMIS as part of our previous study—these providers still used PROMIS in clinical care for their patients. Unexpectedly, two other providers (1 physician and 1 advanced nurse practitioner) reported routinely using PROMIS in clinical care, although they had not participated in the previous study.

The perceived benefits/disadvantages and barriers/facilitators of using PROs in rheumatology care identified by interviewees are summarized in Tables 2-3.

Conclusion: Rheumatology health care providers had a range of attitudes towards the use of PROMIS/PROs in clinical practice and addressing their concerns will be important for promoting the use of PROMIS and other PROs. Demonstrating the value and ease of using PROs in clinical care is essential for gaining support from health care providers.

Acknowledgements:
This study was supported by funding from NIAMS and NIH (T32AR07080 and K24AR063120).

Table 1. Interview participant characteristics (n=8)

Table 2. Perceived benefits/disadvantages of use of patient-reported outcomes in rheumatology care

Table 3. Perceived barriers/facilitators for use of patient-reported outcomes in rheumatology care


Disclosures: Y. Shaw, None; N. Kortam, None; A. Chalak, None; Y. Li, None; F. Reger, None; V. Nagaraja, None; D. Khanna, AbbVie, 2, Acceleron, 2, Actelion, 2, Amgen, 2, Bayer, 2, 5, Boehringer Ingelheim, 2, Bristol-Myers Squibb, 5, CiviBioPharma/Eicos Sciences, Inc, 12, Leadership/Equity position (Chief Medical Officer), Corbus, 2, CSL Behring, 2, Eicos Sciences, Inc, 11, Galapagos NV, 2, Genentech/Roche, 2, Gilead, 2, GlaxoSmithKline, 2, Horizon Therapeutics, 2, 5, Immune Tolerance Network, 5, Merck Sharp & Dohme, 2, Mitsubishi Tanabe Pharma, 2, National Institutes of Health, 5, Pfizer, 5, Sanofi-Aventis, 2, United Therapeutics, 2, Prometheus, 2, Theraly, 2, AstraZeneca, 2.

To cite this abstract in AMA style:

Shaw Y, Kortam N, Chalak A, Li Y, Reger F, Nagaraja V, Khanna D. Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/rheumatology-provider-perspectives-on-using-patient-reported-outcomes-in-clinical-care/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatology-provider-perspectives-on-using-patient-reported-outcomes-in-clinical-care/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology